Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 108Magnetic Resonance Spectroscopy 77Biopsy 76pembrolizumab 59Cyclophosphamide 49fludarabine 40Carboplatin 25Nivolumab 24Cetuximab 23venetoclax 21Radiotherapy 21Cisplatin 21Bevacizumab 20atezolizumab 18X-Rays 18Radiation 17Ipilimumab 17fludarabine phosphate 16Fluorouracil 16Gemcitabine 15Temozolomide 14Paclitaxel 14Leucovorin 14Irinotecan 14Cytarabine 14durvalumab 13Pemetrexed 13Azacitidine 13Oxaliplatin 12CTLA-4 Antigen 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × BAY 1895344 × 30 days × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡